

**Prof. Francesco Grossi**

**Curriculum Vitae et Studiorum**

## **Dati personali**

Cognome: GROSSI  
Nome: Francesco

Indirizzo lavoro: UOC Oncologia Medica  
Università degli Studi dell'Insubria  
Ospedale di Circolo e Fondazione Macchi  
ASST dei Sette Laghi  
Viale Borri, 57  
21100 Varese  
E-mail: [francesco.grossi@uninsubria.it](mailto:francesco.grossi@uninsubria.it)  
[francesco.grossi@asst-settelaghi.it](mailto:francesco.grossi@asst-settelaghi.it)

## **Formazione**

- 23/09/21 Superamento del "Corso di formazione manageriale per dirigente di struttura complessa" codice edizione: DSC 1901/BE. POLIS Lombardia. Università degli Studi di Milano "La Statale".
- 31/10/18 Conseguimento dell'Abilitazione Scientifica Nazionale a professore ordinario (sette concorsuale 06/D3 malattie del sangue, oncologia e reumatologia), Ministero dell'Istruzione, dell'Università e della Ricerca Scientifica.
- 03/12/13 Conseguimento dell'Abilitazione Scientifica Nazionale a professore associato (sette concorsuale 06/D3 malattie del sangue, oncologia e reumatologia), Ministero dell'Istruzione, dell'Università e della Ricerca Scientifica.
- 24/11/11 Superamento del corso: "Ippocrate: Competenze di management per i medici dirigenti "Scuola di Direzione Aziendale (SDA)", Università L. Bocconi Milano.
- 30/10/97 Specialità in Oncologia indirizzo Oncologia Medica (50/50 e lode). Università degli Studi di Genova.
- 30/11/92 Esame di Stato per l'abilitazione alla professione medica (90/90). Università degli Studi di Genova.
- 20/10/92 Laurea in Medicina e Chirurgia (110/110 e lode). Università degli Studi di Genova.

## **Esperienze professionali**

- 1/10/21-ad oggi Professore Associato in Oncologia Medica, Università degli Studi dell'Insubria. Direttore UOC Oncologia Medica, Varese.
- 1/03/21-1/10/21 Direttore UOC Oncologia Medica a tempo pieno e indeterminato con incarico quinquennale presso Ospedale di Circolo e Fondazione Macchi, Varese.
- 01/09/2018-  
28/02/21 Direttore UOC Oncologia Medica a tempo pieno e indeterminato con incarico quinquennale presso Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano.
- 2009 - 2011 Membro del Comitato Tecnico Scientifico (CTS). IRCCS Istituto Nazionale per la Ricerca sul Cancro di Genova.
- 2007- 31/08/18 Coordinatore del Disease Management Team (DMT) sulle neoplasie toraciche. Ospedale Policlinico San Martino (già IRCCS Istituto Nazionale per la Ricerca sul Cancro), Genova.
- 01/02/2003-  
31/08/18 Dirigente Medico a tempo pieno e indeterminato (disciplina Oncologia Medica) presso S.C. Oncologia Medica 2 dell'Ospedale Policlinico San Martino di Genova (già S.C. Oncologia Medica A dell'IRCCS Istituto Nazionale per la Ricerca sul Cancro). Dal 2010 al 31/08/18

Responsabile UOS Tumori Polmonari.

- 01/08/1999-31/01/2003 Dirigente Medico a tempo pieno e indeterminato (disciplina Oncologia Medica) presso Clinica Oncologica, Policlinico Universitario, Azienda Ospedaliera Santa Maria della Misericordia di Udine.
- 01/03/1999-31/07/1999 Dirigente Sanitario a tempo pieno e indeterminato (disciplina Oncologia Medica) presso Clinica Oncologica, Policlinico Universitario, Azienda Ospedaliera Santa Maria della Misericordia di Udine.
- 01/01/1999-28/02/1999 Dirigente Sanitario a tempo pieno e determinato (disciplina Oncologia Medica) presso Clinica Oncologica, Policlinico Universitario, Azienda Ospedaliera Santa Maria della Misericordia di Udine.
- 01/12/1997-31/12/1998 Contrattista ricercatore ai sensi dell'art. 36 del DPR 617/80 in Oncologia Medica. IRCCS Istituto Nazionale per la Ricerca sul Cancro, Genova.
- 1993 - 1997 Specializzando in Oncologia Medica. Università degli Studi di Genova. (con aspettativa per servizio di leva art. 67 D.P.R. 10/1/57 n. 3 dal 14/3/1993 al 13/7/1994 - Corso Allievi ufficiali di Complemento - Scuola di Sanità, Accademia Navale di Livorno - Capo Servizio Sanitario, Maridrogafico Genova).

### **Esperienza Accademica**

- 01/10/21-ad oggi Professore Associato in Oncologia Medica. Università degli Studi dell'Insubria, Varese.
- 02/20-03/21 Professore a contratto a tempo determinato per l'insegnamento di Oncologia modulo "Modelli innovativi di terapia d'induzione con farmaci immunomodulanti nelle neoplasie polmonari non a piccole cellule" SSD Med/06 (2 ore/anno) della Scuola di Specializzazione in Chirurgia Toracica per l'Anno Accademico 2018/2019. Università degli Studi di Milano Statale.
- 02/17- 8/18 Membro del Collegio dei Docenti del Dottorato di Ricerca in "Emato-oncologia e Medicina Interna Clinico-Traslazionale". Università degli Studi di Genova.
- 2015-31/8/18 Incarico di docenza nel Corso di laurea magistrale in Medicina e Chirurgia per l'aa 2017/2018 (sede formativa: GE) nella disciplina "Medicina Interna (cod. 90306)", nell'ambito del Corso Integrato di "Terapia medica applicata e cure palliative (cod. 67571)" anno VI/1° semestre, 8 ore di lezione assegnate - Università degli Studi di Genova.  
Incarico di docenza nel Corso di laurea magistrale in Medicina e Chirurgia per l'aa 2016/2017 (sede formativa: GE) per gli insegnamenti nelle discipline di "Medicina Interna (cod. 90306)", nell'ambito del Corso Integrato di "Terapia medica e cure palliative (cod. 67571)" anno VI/1° semestre, 2 ore di lezione assegnate e di "Attività professionalizzanti cliniche 3 (cod. 90300)", anno IV/2° semestre, 8 ore di esercitazione assegnate. - Università degli Studi di Genova.  
Incarico di docenza nel Corso di laurea magistrale in Medicina e Chirurgia per l'aa 2015/2016 (sede formativa:GE) per gli insegnamenti di "Oncologia Medica (cod. 67436)" nell'ambito del Corso Integrato "Malattie del sangue e oncologia medica (cod. 67431)", anno IV/2° semestre, 8 ore di lezione assegnate e di "Oncologia Medica (cod. 67578)", anno VI/1° semestre, 5 ore di lezione assegnate - Università degli Studi di Genova.
- 2013-2015 Lezioni seminariali (2 ore/anno) nel corso di Laurea Magistrale in Medicina e Chirurgia per l'insegnamento "Oncologia Medica" aa.aa 2012-2013, 2013-2014, 2014-2015. Università degli Studi di Genova.
- 2011-2015 Seminari di approfondimento (2 ore anno) negli aa.aa 2011-2012, 2012-2013, 2013-2014, 2014-2015 nell'ambito del modulo "Chemioterapia antitumorale e nuove terapie antitumorali" del corso "Terapie oncologiche" nella Scuola di Specializzazione in Farmacia Ospedaliera - Dipartimento di Farmacia - Università degli Studi di Genova.
- 2011-2017 Professore a contratto a titolo gratuito nella Scuola di Specializzazione in Oncologia Medica per l'insegnamento "Oncologia Medica" (4 ore/anno) per gli aa.aa 2011-2012, 2012-2013, 2013-2014, 2014-2015, 2015-2016, 2016-2017 - Università degli Studi di Genova.

- 2008-2011 Lezioni seminariali (4 ore/anno) nella Scuola di Specializzazione in Oncologia Medica negli aa.aa. 2008-2009, 2009-2010, 2010-2011. Università degli Studi di Genova.
- 2005 - 2011 Professore a contratto a titolo gratuito nella Scuola di Specializzazione in Chirurgia Toracica per l'insegnamento "Oncologia Polmonare" (2 ore/anno) per gli aa.aa 2005-2006, 2006-2007, 2007-2008, 2008-2009, 2009-2020, 2010-2011. Università degli Studi di Genova.
- 2000-2018 Relatore o co-relatore per tesi di laurea in Medicina e Chirurgia e per tesi di specializzazione in Oncologia Medica, Facoltà di Medicina e Chirurgia, Università degli Studi di Udine, Università degli Studi di Genova.
- 1999 - 2003 Lezioni nella scuola di Specializzazione in Oncologia Medica (2 ore/anno) per gli aa 1999-2000, 2000-2001, 2001-2002, 2002-2003, Università degli Studi di Udine.
- 1999 - 2003 Lezioni nel corso di Oncologia, Facoltà di Medicina e Chirurgia (2 ore/anno) per gli aa 1999-2000, 2000-2001, 2001-2002, 2002-2003, Università degli Studi di Udine.

### **Riconoscimenti**

- 1997 ASCO Merit Award, American Society of Clinical Oncology  
 1997 AIOM Premio per il contributo meritevole, Associazione Italiana di Oncologia Medica

### **Membro delle seguenti società scientifiche**

ASCO American Society of Clinical Oncology  
 ESMO European Society of Medical Oncology  
 IASLC International Association for the Study of Lung Cancer  
 EORTC/Lung Cancer Cooperative Group  
 AIOM Associazione Italiana di Oncologia Medica  
 FONICAP Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone

### **Altri incarichi**

- 2008-2012 Membro della Commissione Nazionale sulla Prevenzione Oncologica - Ministero del Lavoro, della Salute e delle Politiche Sociali.
- 2011-ad oggi Revisore di progetti di Ricerca per: Istituto Toscano Tumori (ITT), Institute National du Cancer (INCa), Hamad Medical Corporation Medical Research Center Qatar.
- 2006-2014 Rater per il McMaster Online Rating of Evidence (MORE) System. Health Information Research Unit of McMaster University (Hamilton, ON Canada).
- 2007-2019 Reviewer per le seguenti riviste: Annals of Oncology, Clinical Cancer Research, British Journal of Cancer, Journal of Thoracic Oncology, Lung Cancer, Chest, Critical Review in Oncology and Hematology, Cancer Chemotherapy and Pharmacology, Oncology, Acta Oncologica, Expert review of Respiratory Medicine, Oncology Reviews, American Journal of Clinical Oncology, Cancer Immunology Immunotherapy, Journal of Thoracic Disease, Cancer Medicine, Molecular Biology Reports, BMC, Current Medical Research and Opinion, Expert Review of Clinical Pharmacology, Expert Review of Anticancer Therapy.

### **Articoli indicizzati in PubMed**

- Indini A, Massi D, Pirro M, Roila F, **Grossi F**, Sahebkar A, Glodde N, Bald T, Mandalà M. Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. Semin Cancer Biol. 2022 Jun 22;S1044-579X(22)00139-0.

2. Scherpereel A, Antonia S, Bautista Y, **Grossi F**, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, McKenna M, Baas P.  
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.  
*Lung Cancer*. 2022 Mar 21;167:8-16.
3. Rijavec E, Biello F, Indini A, **Grossi F**, Genova C.  
Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib.  
*Clin Pharmacol*. 2022 Jan 20;14:1-9.
4. Cortellini A, Giusti R, Filetti M, Citarella F, Adamo V, Santini D, Buti S, Nigro O, Cantini L, Di Maio M, Aerts JGJV, Bria E, Bertolini F, Ferrara MG, Ghidini M, **Grossi F**, Guida A, Berardi R, Morabito A, Genova C, Mazzoni F, Antonuzzo L, Gelibter A, Marchetti P, Chiari R, Macerelli M, Rastelli F, Della Gravara L, Gori S, Tuzi A, De Tursi M, Di Marino P, Mansueto G, Pecci F, Zoratto F, Ricciardi S, Migliorino MR, Passiglia F, Metro G, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Ficorella C, Porzio G, Tiseo M, Russano M, Russo A, Pinato DJ.  
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.  
*J Hematol Oncol*. 2022 Jan 21;15(1):9.
5. Tomasello G, Ghidini M, Galassi B, **Grossi F**, Luciani A, Petrelli F.  
Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis.  
*Sci Rep*. 2022 Jan 20;12(1):1055.
6. Banna GL, Tiseo M, Cortinovis DL, Facchinetti F, Aerts JGJV, Baldessari C, Giusti R, Bria E, **Grossi F**, Berardi R, Morabito A, Catino A, Genova C, Mazzoni F, Gelibter A, Rastelli F, Macerelli M, Chiari R, Gori S, Mansueto G, Citarella F, Cantini L, Rijavec E, Bertolini F, Cappuzzo F, De Toma A, Friedlaender A, Metro G, Pensieri MV, Porzio G, Ficorella C, Pinato DJ, Cortellini A, Addeo A.  
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1  $\geq 50\%$  metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.  
*Thorac Cancer*. 2022 Feb;13(3):483-488.
7. Bonaventura A, Vecchié A, Ruscica M, **Grossi F**, Dentali F.  
PCSK9 as a New Player in Cancer: New Opportunity or Red Herring?  
*Curr Med Chem*. 2022;29(6):960-969.
8. Russano M, Cortellini A, Giusti R, Russo A, Zoratto F, Rastelli F, Gelibter A, Chiari R, Nigro O, De Tursi M, Bracarda S, Gori S, **Grossi F**, Bersanelli M, Calvetti L, Di Noia V, Scartozzi M, Di Maio M, Bossi P, Falcone A, Citarella F, Pantano F, Ficorella C, Filetti M, Adamo V, Veltri E, Pergolesi F, Occhipinti MA, Nicolardi L, Tuzi A, Di Marino P, Macrini S, Inno A, Ghidini M, Buti S, Aprile G, Lai E, Audisio M, Intagliata S, Marconcini R, Brocco D, Porzio G, Piras M, Rijavec E, Simionato F, Natoli C, Tiseo M, Vincenzi B, Tonini G, Santini D.  
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.  
*Cancer Immunol Immunother*. 2022 Apr;71(4):865-874.
9. Carbone F, Ministrini S, Bonaventura A, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, Dal Bello MG, Biello F, Rossi G, Tagliamento M, Alama A, Coco S, Spallarossa P, **Grossi F**, Genova C, Montecucco F.  
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC.  
*Eur J Clin Invest*. 2022 Jan;52(1):e13668.
10. Indini A, Roila F, **Grossi F**, Massi D, Mandalà M.  
Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review.  
*Int J Mol Sci*. 2021 Dec 23;23(1):147.
11. Bao F, Yu F, Hao X, Gu Z, Park SY, **Grossi F**, Fang W.

- Surgical resection of superior pulmonary sulcus tumor after neoadjuvant chemoradiation via the anterior transmanubrial approach: a case report.  
Ann Transl Med. 2021 Oct;9(20):1603.
12. Rijavec E, Genova C, Biello F, Rossi G, Indini A, **Grossi F**.  
Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer.  
Expert Rev Respir Med. 2021 Nov;15(11):1427-1435.
  13. Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, **Grossi F**, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL.  
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.  
Lancet Oncol. 2021 Oct;22(10):1438-1447.
  14. Indini A, Indini A, Costa S, Ierardi AM, Rijavec E, Passoni E, **Grossi F**.  
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report.  
Melanoma Res. 2021 Oct 1;31(5):490-493.
  15. Ghidini M, Ramai D, Facciorusso A, Singh J, Tai W, Rijavec E, Galassi B, **Grossi F**, Indini A.  
Metabolic disorders and the risk of cholangiocarcinoma.  
Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):999-1007.
  16. Gulei D, Indini A, Jerónimo C, Iuga CA, **Grossi F**.  
Cancer Mechanisms and Emerging Therapies.  
Pharmaceutics. 2021 Jul 9;13(7):1045.
  17. **Grossi F**, Jaśkiewicz P, Ferreira M, Czyżewicz G, Kowalski D, Ciuffreda L, Garcia-Gomez R, Caruso S, Bosch-Barrera J, Gautier S, Ta Thanh Minh C, Henriët S, de Castro G Jr.  
Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03).  
Ther Adv Med Oncol. 2021 Jul 16;13:17588359211022905. doi: 10.1177/17588359211022905. PMID: 34349841.
  18. Bauckneht M, Genova C, Rossi G, Rijavec E, Dal Bello MG, Ferrarazzo G, Tagliamento M, Donegani MI, Biello F, Chiola S, Zullo L, Raffa S, Lanfranchi F, Cittadini G, Marini C, Lopci E, Sambuceti G, **Grossi F**, Morbelli S.  
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab.  
Cancers (Basel). 2021 Jun 22;13(13):3117.
  19. Indini A, Turlaki A, **Grossi F**, Gambini D, Brambilla L.  
COVID-19 Vaccination in Patients with Classic Kaposi's Sarcoma.  
Vaccines (Basel). 2021 Jun 10;9(6):632.
  20. Santini D, Zeppola T, Russano M, Citarella F, Anesi C, Buti S, Tucci M, Russo A, Sergi MC, Adamo V, Stucci LS, Bersanelli M, Mazzaschi G, Spagnolo F, Rastelli F, Giorgi FC, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, **Grossi F**, De Tursi M, Di Marino P, Pala L, Queirolo P, Bracarda S, Macrini S, Gori S, Inno A, Zoratto F, Tanda ET, Mallardo D, Vitale MG, Talbot T, Ascierto PA, Pinato DJ, Ficarella C, Porzio G, Cortellini A.  
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.  
J Transl Med. 2021 Jun 24;19(1):270.
  21. Indini A, **Grossi F**, Mandalà M, Taverna D, Audrito V.  
Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications.  
Biomedicines. 2021 May 26;9(6):607.
  22. Indini A, Roila F, **Grossi F**, Massi D, Mandalà M.

- Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?  
Am J Clin Dermatol. 2021 Jul;22(4):511-522.
23. Indini A, Rijavec E, Ghidini M, Cortellini A, **Grossi F**.  
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. *Pharmaceutics*. 2021 May 4;13(5):653.
24. Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Clemente A, Verzoni E, Giusti R, Di Napoli M, Aprile G, Ermacora P, Catino A, Scotti V, Mazzoni F, Guglielmini PF, Vecchia A, Maruzzo M, Rossi E, **Grossi F**, Casadei C, Ficorella C, Montesarchio V, Verderame F, Rizzo M, Guitoli G, Fratino L, Accettura C, Mencoboni M, Zustovich F, Baldessari C, Cinieri S, Camerini A, Laera L, Sorarù M, Zucali PA, Guadalupi V, Leonardi F, Tiseo M, Tognetto M, Di Costanzo F, Pinto C, Negrini G, Russo A, Migliorino MR, Filetti M, Buti S; FICOG group (Federation of Italian Cooperative Oncology Groups).  
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).  
*J Immunother Cancer*. 2021 May;9(5):e002619.
25. Niu Z, Guo S, Cao J, Zhang Y, Guo X, **Grossi F**, Ichiki Y, Li Y, Wang Z.  
Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis. *Ann Transl Med*. 2021 Apr;9(8):705.
26. Indini A, Rijavec E, **Grossi F**.  
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.  
*Int J Mol Sci*. 2021 Apr 30;22(9):4774.
27. Buti S, Bersanelli M, Perrone F, Bracarda S, Di Maio M, Giusti R, Nigro O, Cortinovis DL, Aerts JGJV, Guitoli G, Barbieri F, Ferrara MG, Bria E, **Grossi F**, Bareggi C, Berardi R, Torniai M, Cantini L, Sforza V, Genova C, Chiari R, Rocco D, Della Gravara L, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Citarella F, Russano M, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Follador A, Bissoni R, Tuzi A, Minuti G, Landi L, Ricciardi S, Migliorino MR, Tabbò F, Olmetto E, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Addeo A, Friedlaender A, Cannita K, Porzio G, Ficorella C, Carmisciano L, Pinato DJ, Mazzaschi G, Tiseo M, Cortellini A.  
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.  
*Eur J Cancer*. 2021 Apr 29;150:224-231.
28. Indini A, Rijavec E, **Grossi F**.  
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.  
*Cancers (Basel)*. 2021 Apr 9;13(8):1794.
29. Indini A, **Grossi F**.  
Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial.  
*Lancet Oncol*. 2021 May;22(5):573-575.
30. Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, **Grossi F**, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ.  
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.  
*J Immunother Cancer*. 2021 Apr;9(4):e002421.
31. Di Cosimo S, Tagliaferri B, Generali D, Giudici F, Agustoni F, Bernardo A, Borgonovo K, Farina G, Luchena G, Luciani A, Nolè F, Palmeri L, Pietrantonio F, Poggi G, Zucali PA, Balletti E, Catania G, Bernocchi O, D'Antonio F, Giordano M, **Grossi F**, Lasagna A, La Verde N, Manzoni M, Montagna B, Olgiate A, Raimondi A, Rampinelli I, Verri E, Zaniboni A, Di Maio M, Beretta G, Danova M.

- Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. *Cancers (Basel)*. 2021 Mar 16;13(6):1324.
32. Ghidini M, Indini A, Rijavec E, Bareggi C, Cattaneo M, Tomasello G, Galassi B, Gambini D, **Grossi F**. The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score. *Viruses*. 2021 Mar 19;13(3):508.
33. Indini A, Rijavec E, Ghidini M, Tomasello G, Cattaneo M, Barbin F, Bareggi C, Galassi B, Gambini D, **Grossi F**. Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. *Int J Mol Sci*. 2021 Mar 5;22(5):2628.
34. Indini A, Pinotti G, Artioli F, Aschele C, Bernardi D, Butera A, Defraia E, Fasola G, Gamucci T, Giordano M, Iaria A, Leo S, Ribecco AS, Rossetti R, Savastano C, Schena M, Silva RR, **Grossi F**, Blasi L. Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave. *Eur J Cancer*. 2021 Feb 25;148:112-116.
35. Banna GL, Cortellini A, Cortinovis DL, Tiseo M, Aerts JGJV, Barbieri F, Giusti R, Bria E, **Grossi F**, Pizzutilo P, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Marco R, Cantini L, Nigro O, D'Argento E, Buti S, Minuti G, Landi L, Guaitoli G, Lo Russo G, De Toma A, Donisi C, Friedlaender A, De Giglio A, Metro G, Porzio G, Ficorella C, Addeo A. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1  $\geq 50\%$  advanced non-small-cell lung cancer. *ESMO Open*. 2021 Apr;6(2):100078.
36. Cortellini A, Cannita K, Tiseo M, Cortinovis DL, Aerts JGJV, Baldessari C, Giusti R, Ferrara MG, D'Argento E, **Grossi F**, Guida A, Berardi R, Morabito A, Genova C, Antonuzzo L, Mazzoni F, De Toma A, Signorelli D, Gelibter A, Targato G, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Filetti M, Bracarda S, Citarella F, Marco R, Cantini L, Nigro O, Buti S, Minuti G, Landi L, Ricciardi S, Migliorino MR, Natalizio S, Simona C, De Filippis M, Metro G, Adamo V, Russo A, Spinelli GP, Di Maio M, Banna GL, Friedlaender A, Addeo A, Pinato DJ, Ficorella C, Porzio G. Post-progression outcomes of NSCLC patients with PD-L1 expression  $\geq 50\%$  receiving first-line single-agent pembrolizumab in a large multicentre real-world study. *Eur J Cancer*. 2021 Mar 12;148:24-35.
37. Rijavec E, Indini A, Ghidini M, Tomasello G, Cattaneo M, Barbin F, **Grossi F**. Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. *Expert Rev Anticancer Ther*. 2021 Jul;21(7):705-713.
38. Indini A, Rijavec E, Mandalà M, Castiglioni S, Beltramo G, **Grossi F**. A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday. *Melanoma Res*. 2021 Apr 1;31(2):190-193.
39. Camerini A, Morabito A, Montanino A, Bernabé R, **Grossi F**, Ramlau R, Ciuleanu TE, Ceresoli GL, Pasello G, de Marinis F, Bosch-Barrera J, Laundreau P, Gautier S, Ta Thanh Minh C, Kowalski D. Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial. *ESMO Open*. 2021 Feb 18;6(2):100051.
40. Cortellini A, De Giglio A, Cannita K, Cortinovis DL, Cornelissen R, Baldesari C, Giusti R, D'Argento E, **Grossi F**, Santoni M, Catino A, Berardi R, Sforza V, Rossi G, Antonuzzo L, Di Noia V, Signorelli D, Gelibter A, Occhipinti MA, Follador A, Rastelli F, Chiari R, Gravara LD, Inno A, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Pensieri MV, Russano M, Cantini L, Nigro O, Leonetti A, Bordi P, Minuti G, Landi L, De Toma A, Donisi C, Ricciardi S, Migliorino MR, Napoli VM, Leone G, Metro G, Banna GL, Friedlaender A, Addeo A, Ficorella C, Porzio G.



- Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.  
Thorac Cancer. 2021 Mar;12(6):880-889.
41. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhair Y, Bautista Y, Cornelissen R, Greillier L, **Grossi F**, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G.  
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.  
Lancet. 2021 Jan 30;397(10272):375-386.
42. Indini A, Cattaneo M, Ghidini M, Rijavec E, Bareggi C, Galassi B, Gambini D, Ceriani R, Ceriotti F, Berti E, **Grossi F**.  
Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study.  
Cancer. 2021 Apr 1;127(7):1091-1101.
43. Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Verzoni E, Clemente A, Guadalupi V, Signorelli D, Tiseo M, Giusti R, Filetti M, Di Napoli M, Calvetti L, Cappetta A, Ermacora P, Zara D, Barbieri F, Baldessari C, Scotti V, Mazzoni F, Veccia A, Guglielmini PF, Maruzzo M, Rossi E, **Grossi F**, Casadei C, Cortellini A, Verderame F, Montesarchio V, Rizzo M, Mencoboni M, Zustovich F, Fratino L, Cinieri S, Negrini G, Banzi M, Sorarù M, Zucali PA, Lacidogna G, Russo A, Battelli N, Fornarini G, Mucciari C, Bracarda S, Bonetti A, Pezzuolo D, Longo L, Sartori D, Iannopolo M, Cavanna L, Meriggi F, Tassinari D, Corbo C, Gernone A, Prati V, Carnio S, Giordano P, Dicorato AM, Verusio C, Atzori F, Carrozza F, Gori S, Castro A, Pilotto S, Vaccaro V, Garzoli E, Di Costanzo F, Maiello E, Labianca R, Pinto C, Tognetto M, Buti S.  
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.  
Ther Adv Med Oncol. 2020 Nov 2;12:1758835920968463.
44. Salati M, Caputo F, Baldessari C, Galassi B, **Grossi F**, Dominici M, Ghidini M.  
IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting.  
Cancers (Basel). 2020 Nov 9;12(11):3310.
45. Cortellini A, Ricciuti B, Tiseo M, Bria E, Banna GL, Aerts JG, Barbieri F, Giusti R, Cortinovis DL, Migliorino MR, Catino A, Passiglia F, Torniai M, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Occhipinti MA, Rastelli F, Chiari R, Rocco D, Inno A, De Tursi M, Di Marino P, Mansueto G, Zoratto F, **Grossi F**, Filetti M, Pizzutilo P, Russano M, Citarella F, Cantini L, Targato G, Nigro O, Ferrara MG, Buti S, Scodes S, Landi L, Guaitoli G, Della Gravara L, Tabbò F, Ricciardi S, De Toma A, Friedlaender A, Petrelli F, Addeo A, Porzio G, Ficorella C.  
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression  $\geq 50\%$ : a multicenter study with external validation.  
J Immunother Cancer. 2020 Oct;8(2):e001403.
46. Pagano M, Ceresoli LG, Zucali PA, Pasello G, Garassino M, Grosso F, Tiseo M, Soto Parra H, Zanelli F, Cappuzzo F, **Grossi F**, De Marinis F, Pedrazzoli P, Gnoni R, Bonelli C, Torricelli F, Ciarrocchi A, Normanno N, Pinto C.  
Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study.  
Cancers (Basel). 2020 Oct 13;12(10):2948.
47. Coco S, Boccardo S, Mora M, Fontana V, Vanni I, Genova C, Alama A, Salvi S, Dal Bello MG, Bonfiglio S, Rijavec E, Sini C, Barletta G, Biello F, Carli F, Cavalieri Z, Burrafato G, Longo L, Ballestrero A, **Grossi F**.  
Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer.  
Clin Breast Cancer. 2021 Jun;21(3):218-230.e6.
48. Indini A, Rijavec E, Ghidini M, Cattaneo M, **Grossi F**.  
Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts.  
Eur J Cancer. 2020 Nov;140:161-162.

49. Zaniboni A, Ghidini M, **Grossi F**, Indini A, Trevisan F, Iaculli A, Dottorini L, Moleri G, Russo A, Vavassori I, Brevi A, Rausa E, Boni L, Dondossola D, Valeri N, Ghidini A, Tomasello G, Petrelli, F. A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. *Cancers (Basel)*. 2020 Aug 29;12(9):2452.
50. Dondossola D, Ghidini M, **Grossi F**, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. *World J Gastroenterol*. 2020 Jul 7;26(25):3542-3561.
51. Gelsomino F, Lamberti G, Tiseo M, Rocco D, Pasello G, Cecere FL, Chella A, Grilli G, Mandruzzato M, Tognetto M, Garassino MC, Macerelli M, Novello S, Roila F, Colantonio I, **Grossi F**, Fiorentino M, Ardizzoni A. Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial). *Ther Adv Med Oncol*. 2020 Jul 20;12:1758835920915983.
52. Indini A, Rijavec E, Ghidini M, Bareggi C, Cattaneo M, Galassi B, Gambini D, **Grossi F**. Coronavirus infection and immune system: An insight of COVID-19 in cancer patients. *Crit Rev Oncol Hematol*. 2020 Jul 9; 153:103059.
53. Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, **Grossi F**, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Marco R, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression  $\geq 50\%$  and Their Relationship With Clinical Outcomes. *Clin Lung Cancer*. 2020 Nov;21(6):498-508.e2.
54. Indini A, Rijavec E, Bareggi C, **Grossi F**. Novel treatment strategies for early-stage lung cancer: the oncologist's perspective. *J Thorac Dis*. 2020;12(6):3390-3398.
55. Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, **Grossi F**, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello G, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L; TERA-VOLT investigators. COVID-19 in patients with thoracic malignancies (TERA-VOLT): first results of an international, registry-based, cohort study [published online ahead of print, 2020 Jun 12]. *Lancet Oncol*. 2020 Jul;21(7):914-922.
56. Indini A, Rijavec E, Ghidini M, Cattaneo M, **Grossi F**. Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic. *Eur J Cancer*. 2020 May 31; 135:47-50.
57. Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, **Grossi F**, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G.

- Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of  $\geq 50$  .  
Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221.
- 58.Armeni P, Borsoi L, Fornaro G, Jommi C, **Grossi F**, Costa F.  
Cost-effectiveness and Net Monetary Benefit of durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.  
Clin Ther. 2020 May;42(5):830-847.
- 59.Indini A, Petrelli F, Tomasello G, Rijavec E, Facciorusso A, **Grossi F**, Ghidini M.  
Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis.  
Cancers (Basel). 2020 Apr 18;12(4):998.
- 60.Indini A, Aschele C, Cavanna L, Clerico M, Daniele B, Fiorentini G, Fioretto L, Giordano M, Montesarchio V, Ortega C, Pinotti G, Scanni A, Zamagni C, Blasi L, **Grossi F**.  
Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey.  
Eur J Cancer. 2020 Apr 6; 132:17-23.
- 61.Indini A, Rijavec E, Ghidini M, Bareggi C, Gambini D, Galassi B, Antonelli P, Bettio G, Di Nubila C, **Grossi F**.  
Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.  
Expert Opin Pharmacother. 2020 Jun;21(8):931-940.
- 62.Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell SF, Cheng SY, Bischoff HG, Peled N, **Grossi F**, Jennens RR, Reck M, Garon EB, Novello S, Rubio-Viqueira B, Boyer M, Kurata T, Gray JE, Yang J, Bas T, Pietanza MC, Garassino MC.  
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.  
J Clin Oncol. 2020 May 10;38(14):1505-1517.
- 63.Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, Cabiddu M, Borgonovo K, Dognini G, Brighenti M, De Toma A, Rijavec E, Garassino MC, **Grossi F**, Tomasello G.  
Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.  
Cancers (Basel). 2020 Feb 27;12(3):546.
- 64.Ottonello S, Genova C, Cossu I, Fontana V, Rijavec E, Rossi G, Biello F, Dal Bello MG, Tagliamento M, Alama A, Coco S, Boccardo S, Vanni I, Ferlazzo G, Moretta L, **Grossi F**, Mingari MC, Carrega P, Pietra G.  
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.  
Front Immunol. 2020 Feb 7; 11:125.
- 65.Grizzi G, Ghidini M, Botticelli A, Tomasello G, Ghidini A, **Grossi F**, Fusco N, Cabiddu M, Savio T, Petrelli F. Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options.  
Cancer Manag Res. 2020 Jan 30; 12:675-686.
- 66.Lopez G, Noale M, Corti C, Gaudio G, Sajjadi E, Venetis K, Gambini D, Runza L, Costanza J, Pesenti C, **Grossi F**, Maggi S, Ferrero S, Bosari S, Fusco N.  
PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer.  
Int J Mol Sci. 2020 Feb 21;21(4):1461.
- 67.Indini A, Rijavec E, **Grossi F**.  
Immune related adverse events and response to immunotherapy: Focus on corticosteroids.  
Lung Cancer. 2020 Jul; 145:225.

68. Bonaventura A, **Grossi F**, Carbone F, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, Dal Bello MG, Rossi G, Biello F, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegri F, Genova C, Montecucco F.  
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment.  
*Clin Transl Oncol.* 2020 Sep;22(9):1603-1610.
69. Bonaventura A, **Grossi F**, Montecucco F.  
PCSK9 is a promising prognostic marker in patients with advanced NSCLC.  
*Cancer Immunol Immunother.* 2020 Mar;69(3):491-492.
70. Genova C, Rossi G, Tagliamento M, Rijavec E, Biello F, Carbone L, Zullo L, **Grossi F**.  
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.  
*Expert Rev Respir Med.* 2020 Apr;14(4):367-383.
71. Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambuceti G, Lopci E, Morbelli S, **Grossi F**.  
Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.  
*J Nucl Med.* 2020 Jul;61(7):990-998.
72. Rijavec E, Coco S, Genova C, Rossi G, Longo L, **Grossi F**.  
Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges.  
*Cancers (Basel).* 2019 Dec 19;12(1):17.
73. Landi L, D'Inca F, Gelibter A, Chiari R, **Grossi F**, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta D, Giannarelli D, Soto Parra H, Minuti G, Tiseo M, Migliorino MR, Cognetti F, Toschi L, Bidoli P, Piantedosi F, Calabrò L, Cappuzzo F.  
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.  
*J Immunother Cancer.* 2019 Nov 21;7(1):316.
74. Bruni A, Gaj-Levra N, Ciammella P, Maragna V, Ferrari K, Bonti V, **Grossi F**, Greco S, Greco C, Borghetti P, Franceschini D, Capelletto E, Perna M, Banna G, Vagge S, Baldini E, Bria E, Botti A, Tiseo M, Paci M, Taraborrelli M, Poletti V, Granone P, Ricardi U, Novello S, Scotti V.  
Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach.  
*PLoS One.* 2019 Nov 13;14(11): e0224027.
75. **Grossi F**, Genova C, Crinò L, Delmonte A, Turci D, Signorelli D, Passaro A, Soto Parra H, Catino A, Landi L, Gelsomino F, Tiseo M, Puppo G, Roila F, Ricciardi S, Tonini G, Cognetti F, Toschi L, Tassinari D, Scoppola A, Giannarelli D, Cortesi E.  
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.  
*Eur J Cancer.* 2019 Oct 28; 123:72-80.
76. Genova C, Boccardo S, Mora M, Rijavec E, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Alama A, Vanni I, Barletta G, Bianchi R, Maggioni C, Bruzzi P, **Grossi F**.  
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.  
*J Clin Med.* 2019 Oct 1;8(10):1566.
77. Landi L, Chiari R, Tiseo M, D'Inca F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, **Grossi F**, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.  
Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.  
*Clin Cancer Res.* 2019 Dec 15;25(24):7312-7319.

78. Carbone F, **Grossi F**, Bonaventura A, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, Dal Bello MG, Biello F, Rossi G, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegri F, Genova C, Montecucco F.  
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.  
*Clin Exp Metastasis*. 2019 Oct;36(5):449-456.
79. Ghidini M, Petrillo A, Salati M, Khakoo S, Varricchio A, Tomasello G, **Grossi F**, Petrelli F.  
Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?  
*Cancers (Basel)*. 2019 Aug 1;11(8).
80. Cortinovis D, Chiari R, Catino A, **Grossi F**, DE Marinis F, Sperandi F, Piantedosi F, Vitali M, Parra HJS, Migliorino MR, Tondini C, Tassinari D, Frassoldati A, Verderame F, Pazzola A, Cognetti F, Palmiotti G, Marchetti P, Santoro A, Giannarelli D, Colonese F, Delmonte A.  
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.  
*Anticancer Res*. 2019 Aug;39(8):4265-4271.
81. Bonaventura A, **Grossi F**, Carbone F, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, Dal Bello MG, Rossi G, Biello F, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegri F, Genova C, Montecucco F.  
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study.  
*Cancer Immunol Immunother*. 2019 Aug;68(8):1351-1358.
82. Cappelletto E, Migliorino MR, Morabito A, Chiari R, **Grossi F**, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Conte AD, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.  
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.  
*Lung Cancer*. 2019 Aug; 134:210-217.
83. Santo A, Pilotto S, Galetta D, **Grossi F**, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, Catino A, Follador A, Rijavec E, Genova C, Petrillo P, Favaretto A, Giannone L, Milella M, Tortora G, Giannarelli D, Bria E; Italian association FONICAP (Operative National Interdisciplinary Force against Lung Cancer).  
Maintenance with lanreotide in small-cell lung cancer expressing somatostatin receptors: A multicenter, randomized, phase 3 trial.  
*Lung Cancer*. 2019 Aug; 134:121-126.
84. Alama A, Coco S, Genova C, Rossi G, Fontana V, Tagliamento M, Giovanna Dal Bello M, Rosa A, Boccardo S, Rijavec E, Biello F, Longo L, Cavalieri Z, Bruzzo C, **Grossi F**.  
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab.  
*J Clin Med*. 2019 Jul 10;8(7):1011.
85. Pesce S, Greppi M, **Grossi F**, Del Zotto G, Moretta L, Sivori S, Genova C, Marcenaro E.  
PD-1/PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.  
*Front Immunol*. 2019 Jun 4; 10:1242.
86. Tagliamento M, Genova C, Rossi G, Coco S, Rijavec E, Dal Bello MG, Boccardo S, **Grossi F**, Alama A.  
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds.  
*Expert Opin Investig Drugs*. 2019 Jun;28(6):513-523.
87. Tagliamento M, **Grossi F**, Paolino S, Rijavec E, Genova C, Rossi G, Biello F, De Maria A.  
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus.  
*Immunotherapy*. 2019 Jul;11(10):873-879.

88. Spallarossa P, Tini G, Sarocchi M, Arboscello E, **Grossi F**, Queirolo P, Zoppoli G, Ameri P. Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely. *J Clin Oncol*. 2019 Sep1;37(25):2201-2205.
89. Dono M, De Luca G, Lastraioli S, Anselmi G, Dal Bello MG, Coco S, Vanni I, **Grossi F**, Vigani A, Genova C, Ferrarini M, Ravetti JL, Zupo S. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. *Mol Med*. 2019 Apr 27;25(1):15.
90. Crinò L, Bidoli P, Delmonte A, **Grossi F**, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. *Oncologist*. 2019 Nov;24(11): e1165-e1171.
91. Coco S, Bonfiglio S, Cittaro D, Vanni I, Mora M, Genova C, Dal Bello MG, Boccardo S, Alama A, Rijavec E, Sini C, Rossella V, Barletta G, Biello F, Truini A, Bruzzo C, Gallo M, Lazarevic D, Ballestrero A, **Grossi F**. Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. *Cancers (Basel)*. 2019 Mar 28;11(4).
92. Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, Baglivo S, Dal Bello MG, Ceribelli A, **Grossi F**, Chiari R. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. *Clin Lung Cancer*. 2019 May;20(3):178-185.e2.
93. Dal Bello MG, Filiberti RA, Alama A, Orengo AM, Mussap M, Coco S, Vanni I, Boccardo S, Rijavec E, Genova C, Biello F, Barletta G, Rossi G, Tagliamento M, Maggioni C, **Grossi F**. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. *J Transl Med*. 2019 Mar 8;17(1):74.
94. Crinò L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC, Proto C, Cappuzzo F, **Grossi F**, Tonini G, Sarobba MG, Pinotti G, Numico G, Samaritani R, Ciuffreda L, Frassoldati A, Bregni M, Santo A, Piantedosi F, Illiano A, De Marinis F, Tamperi S, Giannarelli D, Delmonte A. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. *Lung Cancer*. 2019 Mar; 129:35-40.
95. Cusato J, Genova C, Tomasello C, Carrega P, Ottonello S, Pietra G, Mingari MC, Cossu I, Rijavec E, Leggieri A, Di Perri G, Dal Bello MG, Coco S, Boccardo S, Ferlazzo G, **Grossi F**, D'Avolio A. Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. *Cancers (Basel)*. 2019 Jan 21;11(1):125.
96. Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, **Grossi F**, Chiari R. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. *J Cancer Res Clin Oncol*. 2019 Feb;145(2):479-485.
97. Wang C, Xu F, Shen J, Zhang L, Zhang J, Jin J, Ampollini L, van Schil P, Kimura H, **Grossi F**, Suda K, Zhang B, Ma D; written on behalf of the AME Lung Cancer Collaborative Group. Successful treatment of lung adenocarcinoma with gefitinib based on *EGFR* gene amplification. *J Thorac Dis*. 2018 Nov;10(11):E779-E783
98. Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, **Grossi F**.

- Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.  
*Expert Opin Pharmacother.* 2018 Dec;19(18):2055-2062. Erratum in: *Expert Opin Pharmacother.* 2018 Dec;19(18):9.
99. Rossi G, Alama A, Genova C, Rijavec E, Tagliamento M, Biello F, Coco S, Dal Bello MG, Boccardo S, **Grossi F**.  
 The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer.  
*Expert Opin Pharmacother.* 2018 Dec;19(17):1969-1976.
100. Barbone F, Barbiero F, Belvedere O, Rosolen V, Giangreco M, Zanin T, Pisa FE, Meduri S, Follador A, **Grossi F**, Fasola G.  
 Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers.  
*Int J Epidemiol.* 2018 Dec 1;47(6):1981-1991.
101. Gridelli C, de Castro Carpeno J, Dingemans AC, Griesinger F, **Grossi F**, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J.  
 Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.  
*JAMA Oncol.* 2018 Dec 1;4(12): e183486. Erratum in: *JAMA Oncol.* 2018 Dec 1;4(12):1792.
102. Gregorc V, Cavina R, Novello S, **Grossi F**, Lazzari C, Capelletto E, Genova C, Salini G, Lambiase A, Santoro A.  
 NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.  
*Oncologist.* 2018 Oct;23(10):1133-e112.
103. **Grossi F**, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F.  
 Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.  
*Eur J Cancer.* 2018 Sep; 100:126-134.
104. Gridelli C, Ascierto PA, **Grossi F**, Baldini E, Favaretto A, Garassino MC, Morabito A, Migliorino MR, Rossi A, de Marinis F.  
 Second-line treatment of advanced non-small cell lung cancer non-oncogene addicted: new treatment algorithm in the era of novel immunotherapy.  
*Curr Clin Pharmacol.* 2018;13(2):76-84.
105. Fasola G, De Carlo E, **Grossi F**.  
 Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.  
*Recenti Prog Med.* 2018 Jun;109(6):328-332.
106. de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, **Grossi F**, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.  
 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).  
*ESMO Open.* 2018 May 31;3(4): e000298.
107. Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, **Grossi F**, Genova C.  
 CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.  
*Expert Opin Biol Ther.* 2018 Jul;18(7):829-835.
108. Gregorc V, Gaafar RM, Favaretto A, **Grossi F**, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M.  
 NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.  
*Lancet Oncol.* 2018 Jun;19(6):799-811.

109. Garassino MC, Gelibter AJ, **Grossi F**, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Quadri S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, Lo Russo G, de Marinis F.  
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.  
J Thorac Oncol. 2018 Aug;13(8):1146-1155.
110. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, **Grossi F**, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators.  
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.  
N Engl J Med. 2018 May 31;378(22):2078-2092.
111. Sarocchi M, **Grossi F**, Arboscello E, Bellodi A, Genova C, Dal Bello MG, Rijavec E, Barletta G, Rossi G, Biello F, Ghigliotti G, Canepa M, Mussap M, Brunelli C, Spallarossa P.  
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.  
Oncologist. 2018 Aug;23(8):936-942.
112. **Grossi F**, Genova C, Rijavec E, Barletta G, Biello F, Dal Bello MG, Meyer K, Roder J, Roder H, Grigorieva J  
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.  
Lung Cancer. 2018 Mar; 117:64-69.
113. Spallarossa P, Meliota G, Brunelli C, Arboscello E, Ameri P, Dessalvi CC, **Grossi F**, Deidda M, Mele D, Sarocchi M, Bellodi A, Madonna R, Mercurio G.  
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects.  
Med Res Rev. 2018 Sep;38(5):1447-1468.
114. Genova C, Rijavec E, **Grossi F**.  
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?  
J Thorac Dis. 2017 Nov;9(11):4300-4304.
115. Truini A, Coco S, Nadal E, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Biello F, Barletta G, Merlo DF, Valentino A, Ferro P, Ravetti GL, Stigliani S, Vigani A, Fedeli F, Beer DG, Roncella S, **Grossi F**.  
Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.  
Oncotarget. 2017 Aug 2;8(40):68627-68640.
116. Alama A, Coco S, Vanni I, **Grossi F**.  
Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".  
Int J Mol Sci. 2017 Jun 19;18(6).
117. Dal Bello MG, Alama A, Coco S, Vanni I, **Grossi F**.  
Understanding the checkpoint blockade in lung cancer immunotherapy.  
Drug Discov Today. 2017 Aug;22(8):1266-1273.
118. Vanni I, Alama A, **Grossi F**, Dal Bello MG, Coco S.  
Exosomes: a new horizon in lung cancer.  
Drug Discov Today. 2017 Jun;22(6):927-936.
119. Coco S, Alama A, Vanni I, Fontana V, Genova C, Dal Bello MG, Truini A, Rijavec E, Biello F, Sini C, Burrafato G, Maggioni C, Barletta G, **Grossi F**.



- Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.  
Int J Mol Sci. 2017 May 11;18(5).
120. Genova C, Rossi G, Rijavec E, Biello F, Barletta G, Tagliamento M, **Grossi F**.  
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.  
Expert Opin Drug Saf. 2017 Apr 19;1-13.
121. Rijavec E, Genova C, Barletta G, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Vanni I, Boccardo S, Alama A, **Grossi F**.  
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.  
Expert Opin Investig Drugs. 2017 May;26(5):551-561.
122. Morbelli S, Alama A, Ferrarazzo G, Coco S, Genova C, Rijavec E, Bongioanni F, Biello F, Dal Bello MG, Barletta G, Massollo M, Vanni I, Piva R, Nieri A, Bauckneht M, Sambuceti G, **Grossi F**.  
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): an (18)F-FDG PET/CT study.  
J Nucl Med. 2017 Nov;58(11):1764-1769.
123. Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, Brighenti M, Zanelli F, Defraia E, Chiari R, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Trolese AR, **Grossi F**, Riccardi F, Ardizzoni A.  
Italian, Multicenter Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.  
J Clin Oncol. 2017 Apr 20;35(12):1281-1287.
124. Bauckneht M, Piva R, Sambuceti G, **Grossi F**, Morbelli S.  
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?  
World J Radiol. 2017 Feb 28;9(2):27-33.
125. **Grossi F**, Rijavec E, Genova C, Barletta G, Biello F, Maggioni C, Burrafato G, Sini C, Dal Bello MG, Meyer K, Roder J, Roder H, Grigorieva J.  
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.  
Br J Cancer. 2017 Jan 3;116(1):36-43.
126. Genova C, Rijavec E, Biello F, Rossi G, Barletta G, Dal Bello MG, Vanni I, Coco S, Alama A, **Grossi F**.  
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.  
Expert Opin Pharmacother. 2017 Jan;18(1):19-33.
127. Genova C, Alama A, Coco S, Rijavec E, Dal Bello MG, Vanni I, Biello F, Barletta G, Rossi G, **Grossi F**.  
Vinflunine for the treatment of non-small cell lung cancer.  
Expert Opin Investig Drugs. 2016 Dec;25(12):1447-1455.
128. **Grossi F**.  
New perspectives in second-line treatment in non-squamous non-small cell lung cancer.  
Recenti Prog Med. 2016 Dec;107(12):641-646.
129. Vanni I, Coco S, Bonfiglio S, Cittaro D, Genova C, Biello F, Mora M, Rossella V, Dal Bello MG, Truini A, Banelli B, Lazarevic D, Alama A, Rijavec E, Barletta G, **Grossi F**.  
Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report.  
Medicine (Baltimore). 2016 Nov;95(48): e5447.
130. Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, **Grossi F**, D'Alessandro V, de Marinis F, Barbera S, Caroti C, Favaretto A, Cortinovis D, Morrica B, Tixi L, Ceschia T, Parisi S, Ricardi U, Grimaldi A, Loreggian L, Navarria P, Huber RM, Belani C, Bruswig PF, Scagliotti GV, Scolaro T.  
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.

- Lung Cancer. 2016 Oct; 100:30-7.
131. **Grossi F**, Bennouna J, Havel L, Hochmair M, Almodovar T.  
Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries.  
Curr Med Res Opin. 2016 Sep;32(9):1577-84.
  132. Bonfiglio S, Vanni I, Rossella V, Truini A, Lazarevic D, Dal Bello MG, Alama A, Mora M, Rijavec E, Genova C, Cittaro D, **Grossi F**, Coco S.  
Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.  
BMC Cancer. 2016 Aug 30; 16:692.
  133. Maggioni C, Barletta G, Rijavec E, Biello F, Gualco E, **Grossi F**.  
Advances in treatment of mesothelioma.  
Expert Opin Pharmacother. 2016 Jun;17(9):1197-205.
  134. Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, **Grossi F**, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators.  
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.  
Ann Oncol. 2016 Mar;27(3):417-23.
  135. Genova C, Rijavec E, **Grossi F**.  
Hematopoietic growth factors in lung cancer.  
Curr Opin Oncol. 2016 Mar;28(2):135-44.
  136. Biello F, Burrafato G, Rijavec E, Genova C, Barletta G, Truini A, Coco S, Dal Bello MG, Alama A, Boccardo F, **Grossi F**.  
Fibroblast Growth Factor Receptor (FGFR): A new target for non-small cell lung cancer therapy.  
Anticancer Agents Med Chem. 2016;16(9):1142-54.
  137. Genova C, Rijavec E, **Grossi F**.  
Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers.  
Expert Rev Anticancer Ther. 2016;16(1):1-4.
  138. Truini A, Coco S, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Barletta G, Biello F, Maggioni C, **Grossi F**.  
Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.  
Microna. 2016;5(1):12-18.
  139. Dal Bello MG, Alama A, Barletta G, Coco S, Truini A, Vanni I, Boccardo S, Genova C, Rijavec E, Biello F, Bottoni G, Sambuceti G, **Grossi F**.  
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.  
Int J Cancer. 2015 Dec 15;137(12):2947-58.
  140. Vanni I, Coco S, Truini A, Rusmini M, Dal Bello MG, Alama A, Banelli B, Mora M, Rijavec E, Barletta G, Genova C, Biello F, Maggioni C, **Grossi F**.  
Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.  
Int J Mol Sci. 2015 Dec 3;16(12):28765-82.
  141. Vansteenkiste JF, Canon JL, Braud FD, **Grossi F**, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC.  
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.  
J Thorac Oncol. 2015 Sep;10(9):1319-27.

142. Coco S, Truini A, Alama A, Dal Bello MG, Venè R, Garuti A, Carminati E, Rijavec E, Genova C, Barletta G, Sini C, Ballestrero A, Boccardo F, **Grossi F**.  
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.  
Target Oncol. 2015 Sep;10(3):393-404.
143. Alama A, Gangemi R, Ferrini S, Barisione G, Orengo AM, Truini M, Bello MG, **Grossi F**.  
CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib.  
Arch Immunol Ther Exp (Warsz). 2015 Jun;63(3):207-14.
144. Coco S, Truini A, Vanni I, Genova C, Rosano C, Dal Bello MG, Alama A, Venè R, Rijavec E, Barletta G, Biello F, Boccardo F, **Grossi F**.  
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma.  
J Thorac Oncol. 2015 Jun;10(6): e50-2.
145. Cappuzzo F, Finocchiaro G, **Grossi F**, Bidoli P, Favaretto A, Marchetti A, Valente ML, Cseh A, Clementi L, Massey D, Santoro A.  
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.  
J Thorac Oncol. 2015 Apr;10(4):665-72.
146. Coco S, Truini A, Vanni I, Dal Bello MG, Alama A, Rijavec E, Genova C, Barletta G, Sini C, Burrafato G, Biello F, Boccardo F, **Grossi F**.  
Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine.  
Curr Drug Targets. 2015;16(1):47-59.
147. **Grossi F**, Dal Bello MG, Salvi S, Puzone R, Pfeffer U, Fontana V, Alama A, Rijavec E, Barletta G, Genova C, Sini C, Ratto GB, Taviani M, Truini M, Merlo DF.  
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.  
Dis Markers. 2015; 2015:302649.
148. Rijavec E, Biello F, Genova C, Barletta G, Maggioni C, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Beltramini S, Grassi MA, Boccardo F, **Grossi F**.  
Belagenpumatucel-L for the treatment of non-small cell lung cancer.  
Expert Opin Biol Ther. 2015;15(9):1371-9.
149. Genova C, Rijavec E, **Grossi F**.  
Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?  
Curr Med Res Opin. 2014 Jul 11:1-3.
150. Natale R, Blackhall F, Kowalski D, Ramlau R, Bepler G, **Grossi F**, Lerchenmüller C, Pinder Schenck M, Mezger J, Danson S, Gadgeel SM, Summers Y, Callies S, André V, Das M, Lahn M, Talbot D.  
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.  
J Thorac Oncol. 2014 Nov;9(11):1704-8.
151. Aprile G, Rijavec E, Fontanella C, Rihawi K, **Grossi F**.  
Ramucirumab: preclinical research and clinical development.  
Onco Targets Ther. 2014 Oct 29; 7:1997-2006.
152. Alama A, Truini A, Coco S, Genova C, **Grossi F**.  
Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer.  
Drug Discov Today. 2014 Oct;19(10):1671-6.
153. Genestreti G, **Grossi F**, Genova C, Burgio MA, Bongiovanni A, Gavelli G, Bartolotti M, Di Battista M, Cavallo G, Brandes AA.  
Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview.  
Future Oncol. 2014 Oct;10(13):2081-96.

154. Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, Cappuzzo F, **Grossi F**, Santo A, Cortinovis D, Favaretto A, Lorusso V, Galetta D, Siena S, Bettini A, Iurlaro M, Caprioli A; on behalf of LIFE study team.  
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.  
*J Cancer Res Clin Oncol.* 2014 Oct;140(10):1783-93.
155. Truini A, Alama A, Dal Bello MG, Coco S, Vanni I, Rijavec E, Genova C, Barletta G, Biello F, **Grossi F**.  
Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System.  
*Front Oncol.* 2014 Sep 4; 4:242.
156. de Marinis F, Ardizzoni A, Fontanini G, **Grossi F**, Cappuzzo F, Novello S, Santo A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C; LIFE study team.  
Management of Italian Patients With Advanced Non-Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study.  
*Clin Lung Cancer.* 2014 Sep;15(5):338-45.
157. Truini A, Coco S, Alama A, Genova C, Sini C, Dal Bello MG, Barletta G, Rijavec E, Burrafato G, Boccardo F, **Grossi F**.  
Role of microRNAs in malignant mesothelioma.  
*Cell Mol Life Sci.* 2014 Aug;71(15):2865-78.
158. Rijavec E, Genova C, Barletta G, Biello F, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Boccardo F, **Grossi F**.  
Efficacy of motesanib diphosphate in non-small-cell lung cancer.  
*Expert Opin Pharmacother.* 2014 Aug;15(12):1771-80.
159. Barletta G, Genova C, Rijavec E, Burrafato G, Biello F, Sini C, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Beltramini S, Grassi MA, Boccardo F, **Grossi F**.  
Oral vinorelbine in the treatment of non-small-cell lung cancer.  
*Expert Opin Pharmacother.* 2014 Aug;15(11):1585-99.
160. von Pawel J, Gorbounova V, Reck M, Kowalski DM, Allard A, Chadja M, Rey A, Bennouna J, **Grossi F**.  
DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.  
*Lung Cancer.* 2014 Aug;85(2):224-9.
161. Rijavec E, Genova C, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, **Grossi F**.  
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.  
*Expert Opin Biol Ther.* 2014 Jul;14(7):1007-17.
162. Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, **Grossi F**, Pas TD, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsypin M, Roder J, Doglioni C, Levra MG, Petrelli F, Foti S, Viganò M, Bachi A, Roder H.  
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.  
*Lancet Oncol.* 2014 Jun;15(7):713-21.
163. Gridelli C, Novello S, Zilembo N, Luciani A, Favaretto AG, De Marinis F, Genestreti G, Crinò L, **Grossi F**, Caffo O, Ferrà F, Cruciani G, Brandes AA, Galetta D, Barni S, Fasola G, Cerea G, Ferrari S, Iannacone C, Ciardiello F.  
Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Elderly Patients.  
*J Thorac Oncol.* 2014 May;9(5):733-7.
164. Genova C, Rijavec E, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, **Grossi F**.  
Afinib for the treatment of advanced non-small-cell lung cancer.

- Expert Opin Pharmacother. 2014 Apr;15(6):889-903.
165. Rijavec E, Genova C, Alama A, Barletta G, Sini C, Pronzato P, Coco S, Bello MG, Savarino G, Truini A, Boccardo F, **Grossi F**.  
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.  
Future Oncol. 2014 Jan;10(1):79-90.
166. Groen HJ, Socinski MA, **Grossi F**, Juhasz E, Gridelli C, Baas P, Butts CA, Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, Tye L, Chao RC, Blumenschein GR Jr.  
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).  
Ann Oncol. 2013 Sep;24(9):2382-9.
167. O'Brien ME, Gaafar RM, Popat S, **Grossi F**, Price A, Talbot DC, Cufer T, Ottensmeier C, Danson S, Pallis A, Hasan B, Van Meerbeeck JP, Baas P.  
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).  
Eur J Cancer. 2013 Sep;49(13):2815-22.
168. Puzone R, Savarino G, Salvi S, Dal Bello MG, Barletta G, Genova C, Rijavec E, Sini C, Esposito AI, Ratto GB, Truini M, **Grossi F**, Pfeffer U.  
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients.  
Mol Cancer. 2013 Aug 29;12(1):97.
169. Ceresoli GL, Zucali PA, Mencoboni M, Botta M, **Grossi F**, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A.  
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.  
Br J Cancer. 2013 Aug 6;109(3):552-8.
170. Genova C, Rijavec E, Truini A, Coco S, Sini C, Barletta G, Dal Bello MG, Alama A, Savarino G, Pronzato P, Boccardo F, **Grossi F**.  
Pemetrexed for the treatment of non-small cell lung cancer.  
Expert Opin Pharmacother. 2013 Aug;14(11):1545-58.
171. **Grossi F**, Genova C, Gaitan ND, Dal Bello MG, Rijavec E, Barletta G, Sini C, Donato C, Beltramini S, Pronzato P, Porcile G, Boccardo F, Walzer S.  
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy.  
Lung Cancer. 2013 Aug;81(2):236-40.
172. Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, **Grossi F**, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini N, Azzoni C, Bordi C, Ardizzoni A.  
Bio-FAST trial group. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.  
Br J Cancer. 2013 Apr 30;108(8):1695-703.
173. Sconfienza LM, Mauri G, **Grossi F**, Truini M, Serafini G, Sardanelli F, Murolo C.  
Pleural and Peripheral Lung Lesions: Comparison of US- and CT-guided Biopsy.  
Radiology. 2013 Mar;266(3):930-5.
174. Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, Ratto GB, **Grossi F**, Truini M, Pistillo MP.  
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.  
Cancer Immunol Immunother. 2012 Sep;61(9):1463-72.
175. Genova C, Rijavec E, Barletta G, Sini C, Dal Bello MG, Truini M, Murolo C, Pronzato P, **Grossi F**.

- Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer.  
Expert Opin Biol Ther. 2012 Jul;12(7):939-48.
176. **Grossi F**.  
Management of non-small cell lung in cancer patients with stable disease.  
Drugs. 2012 Jun 19;72 Suppl 1:20-7.
177. **Grossi F**, Rijavec E, Dal Bello MG, Defferrari C, Brianti A, Barletta G, Genova C, Murolo C, Cosso M, Fontanini G, Boldrini L, Truini M, Pronzato P.  
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.  
Cancer Chemother Pharmacol. 2012 Jun;69(6):1407-12.
178. Nuijten MJ, de Castro Carpeño J, Chouaid C, Vergnenègre A, **Grossi F**, Bischoff H, Heigener D, Walzer S.  
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.  
Lung Cancer. 2012 Jun;76(3):465-71.
179. Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, **Grossi F**, Germano D, Matano E, Marini G, Labianca R, Di Costanzo F, Bagnulo A, Pennucci C, Caroti C, Mencoboni M, Zanelli F, Prochilo T, Cafferata MA, Ardizzoni A.  
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).  
Br J Cancer. 2012 Feb 14;106(4):658-65.
180. **Grossi F**, de Marinis F, Gebbia V, Riccardi F, Caffo O, Gamucci T, Ferrà F, Nardi M, Moscetti L, Boni L, Dondi D, Galligioni E.  
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.  
Cancer Chemother Pharmacol. 2012 Feb;69(2):369-75.
181. Vergnenègre A, Ray JA, Chouaid C, **Grossi F**, Bischoff HG, Heigener DF, Walzer F.  
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.  
Clinicoecon Outcomes Res. 2012; 4:31-7.
182. Bello C, Dal Bello G, Cea M, Nahimana A, Aubry D, Garuti A, Motta G, Moran E, Fruscione F, Pronzato P, **Grossi F**, Patrone F, Ballestrero A, Dupuis M, Sordat B, Zimmermann K, Loretan J, Wartmann M, Duchosal MA, Nencioni A, Vogel P.  
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols.  
Bioorg Med Chem 2011 Dec 15;19(24):7720-7.
183. Gridelli C, Bennouna J, de Castro J, Dingemans AM, Griesinger F, **Grossi F**, Rossi A, Thatcher N, Wong EK, Langer C.  
Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial.  
Clin Lung Cancer. 2011 Nov;12(6):407-11.
184. Novello S, Camps C, **Grossi F**, Mazieres J, Abrey L, Vernejoux JM, Thall A, Patyna S, Usari T, Wang Z, Chao RC, Scagliotti G.  
Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases.  
J Thorac Oncol. 2011 Jul;6(7):1260-6.
185. Banz K, Bischoff H, Brunner M, Chouaid C, de Castro Carpeño J, de Marinis F, **Grossi F**, Vergnenègre A, Walzer S.  
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.

- Lung Cancer. 2011 Dec;74(3):529-34.
186. Belvedere O, Follador A, Rossetto C, Merlo V, Defferrari C, Sibau AM, Aita M, Dal Bello MG, Meduri S, Gaiardo M, Fasola G, **Grossi F**.  
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).  
Eur J Cancer. 2011 Jul;47(11):1653-9.
187. **Grossi F**, Kubota K, Cappuzzo F, de Marinis F, Gridelli C, Aita M, Douillard JY.  
Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.  
Oncologist. 2010;15(10):1102-12.
188. Giuliani G, **Grossi F**, de Marinis F, Walzer S.  
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.  
Lung Cancer. 2010 Aug;69 Suppl 1:S11-7. Erratum in: Lung Cancer. 2010 Aug;69 Suppl 1:S32.
189. **Grossi F**, Spizzo R, Bordo D, Cacitti V, Valent F, Rossetto C, Follador A, Di Terlizzi S, Aita M, Morelli A, Fasola G, Consiglieri C, Ceschia T, Beltrami CA, Belvedere O.  
Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014).  
J Thorac Oncol. 2010 Sep;5(9):1354-1360.
190. Scagliotti G, Novello, von Pawel JS, Reck M, Rodrigues Pereira J, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller K, Arén O, Csollak M, Albert I, Barrios CE, **Grossi F**, Krzakowski M, Cupit L, Cihon F, DiMatteo S, and Hanna N.  
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non-Small-Cell Lung Cancer.  
J Clin Oncol. 2010 Apr 10;28(11):1835-42.
191. Borcard F, Baud M, Bello C, Dal Bello G, **Grossi F**, Pronzato P, Cea M, Nencioni A, Vogel P.  
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity  
Bioorg Med Chem Lett. 2010 Sep 1;20(17):5353-6.
192. Bello C, Cea M, Dal Bello G, Garuti A, Rocco I, Cirmena G, Moran E, Nahimana A, Duchosal MA, Fruscione F, Pronzato P, **Grossi F**, Patrone F, Ballestrero A, Dupuis M, Sordat B, Nencioni A, Vogel P.  
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as  $\alpha$ -mannosidase inhibitors and with antitumor activities against hematological and solid malignancies.  
Bioorg Med Chem. 2010 May 1;18(9):3320-34.
193. Airoidi I, Di Carlo E, Cocco C, Caci E, Cilli M, Sorrentino C, Sozzi G, Ferrini S, Rosini S, Bertolini G, Truini M, **Grossi F**, Galiotta LJ, Ribatti D, Pistoia V.  
IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.  
PLoS One. 2009 Jul 1;4(7): e6119.
194. Rotondo R, Barisione G, Mastracci L, **Grossi F**, Orengo AM, Costa R, Truini M, Fabbi M, Ferrini S, Barbieri O.  
IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer.  
Int J Cancer. 2009 Aug 15;125(4):887-93.
195. **Grossi F**, Aita M, Defferrari C, Rosetti F, Brianti A, Fasola G, Vinante O, Pronzato P, Pappagallo G.  
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.  
Oncologist. 2009 May;14(5):497-510.
196. Tiseo M, Gridelli C, Cascinu S, Crinò L, Piantedosi FV, **Grossi F**, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P, Ardizzoni A.

- An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy.  
Lung Cancer. 2009 May;64(2):199-206.
197. **Grossi F**, de Marinis F, Frontini L, Gridelli C.  
The dilemma of first-line chemotherapy in advanced non-small-cell lung cancer: are third-generation drugs all the same?  
Tumori. 2008 May-Jun;94(3):5-14.
198. Aita M, Fasola G, Defferrari C, Brianti A, Dal Bello MG, Follador A, Sinaccio G, Pronzato P, **Grossi F**.  
Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.  
Crit Rev Oncol Hematol. 2008 Dec;68(3):183-96.
199. Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, **Grossi F**, Cortinovia D, Del Conte G, Ceribelli A, Bearz A, Salamina S, De Vincenzo F, Cappuzzo F, Marangolo M, Torri V, Santoro A.  
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.  
Br J Cancer. 2008 Jul 8;99(1):51-6.
200. Rotondo R, Mastracci L, Piazza T, Barisione G, Fabbi M, Cassanello M, Costa R, Morandi B, Astigiano S, Cesario A, Sormani MP, Ferlazzo G, **Grossi F**, Ratto GB, Ferrini S, Frumento G.  
Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression.  
Int J Cancer. 2008 Sep 1;123(5):1108-16.
201. Tiseo M, Ardizzoni A, Cafferata MA, Loprevite M, Chiaramondia M, Filiberti R, Marroni P, **Grossi F**, Paganuzzi M.  
Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer.  
Anticancer Res. 2008 Jan-Feb;28(1B):507-13.
202. de Marinis F, **Grossi F**.  
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.  
Oncologist. 2008;13 Suppl 1:14-20.
203. **Grossi F**, Gridelli C, Aita M, De Marinis F.  
Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer.  
Crit Rev Oncol Hematol. 2008 Jul;67(1):16-26.
204. Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi E, Crinò L, De Marinis F, Di Pietro FA, **Grossi F**, Innocenzi D, Micali G, Piantedosi FV, Scartozzi M.  
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.  
Crit Rev Oncol Hematol. 2008 May;66(2):155-62.
205. Loprevite M, Tiseo M, Chiaramondia M, Capelletti M, Bozzetti C, Bortesi B, Naldi N, Nizzoli R, Dadati P, Kunkl A, Zennaro D, Lagrasta C, Campanini N, Spiritelli E, Camisa R, **Grossi F**, Rindi G, Franciosi V, Ardizzoni A.  
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.  
Clin Cancer Res. 2007 Nov 1;13(21):6518-26.
206. Fasola G, Belvedere O, Aita M, Zanin T, Follador A, Cassetti P, Meduri S, De Pangher V, Pignata G, Rosolen V, Barbone F, **Grossi F**.  
Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial - an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).  
Oncologist. 2007 Oct;12(10):1215-24.
207. **Grossi F**, Aita M.  
Bevacizumab and non-small-cell lung cancer: starving the enemy to survive.  
Expert Opin Biol Ther. 2007 Jul;7(7):1107-19.



208. Gridelli C, Ferrara C, Guerriero C, Palazzo S, Grasso G, Pavese I, Satta F, Bajetta E, Cortinovis D, Barbieri F, Gebbia V, **Grossi F**, Novello S, Baldini E, Gasparini G, Latino W, Durante E, Giustini L, Negrini C. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. *J Thorac Oncol*. 2007 Jun;2(6):475-80. Erratum in: *J Thorac Oncol*. 2007 Jul;2(7):676.
209. **Grossi F**, Aita M, Follador A, Defferrari C, Brianti A, Sinaccio G, Belvedere O. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. *Oncologist*. 2007 Apr;12(4):451-64.
210. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, **Grossi F**, Paganuzzi M. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. *Cancer*. 2006 Dec 15;107(12):2842-9.
211. **Grossi F**, Tiseo M. Granulocyte growth factors in the treatment of non-small cell lung cancer(NSCLC). *Crit Rev Oncol Hematol*. 2006 Jun;58(3):221-30.
212. Rinaldi M, Belvedere O, Cauchi C, Defferrari C, Viola G, **Grossi F**. Maintenance chemotherapy in non-small cell lung cancer. *Ann Oncol*. 2006 Mar;17 Suppl 2: ii67-70.
213. Ceresoli GL, Zucali PA, Favaretto AG, **Grossi F**, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morengi E, Cavina R, Marangolo M, Parra HJ, Santoro A. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. *J Clin Oncol*. 2006 Mar 20;24(9):1443-8.
214. Benasso M, Ponzanelli A, Merlano M, Numico G, Ricci I, Vigo V, **Grossi F**, Amadori D, Cavallo G, Capaccetti B, Taveggia P, Boni L, Rosso R. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group. *Acta Oncol*. 2006;45(2):168-74.
215. **Grossi F**, Fasola G, Rossetto C, Spizzo R, Meduri S, Sibau A, Vigevani E, Tumolo S, Adami G, Sacco C, Recchia L, Rizzato S, Ceschia T, Belvedere O. Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). *Lung Cancer*. 2006 Apr;52(1):89-92.
216. Belvedere O, **Grossi F**. Lung Cancer Highlights from ASCO 2005. *Oncologist*. 2006 Jan;11(1):39-50.
217. Tiseo M, Franciosi V, **Grossi F**, Ardizzoni A. Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice? *Eur J Cancer*. 2006 Jan;42(1):8-16.
218. Belvedere O, **Grossi F**. To treat or not to treat advanced non-small-cell lung cancer patients with impaired performance status? *J Clin Oncol*. 2005 Oct 1;23(28):7231-2.
219. Loprevite M, Tiseo M, **Grossi F**, Scolaro T, Semino C, Pandolfi A, Favoni R, Ardizzoni A. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. *Oncol Res*. 2005;15(1):39-48.
220. **Grossi F**, Belvedere O, Fasola G, Ceschia T, Meduri S, Sibau A, Sacco C, Bazzocchi M, Talmassons G, Morelli A, Barbone F, Sobrero A. Tumor measurements on computed tomographic images of non-small cell lung cancer were similar among cancer professionals from different specialties.

- J Clin Epidemiol. 2004 Aug;57(8):804-8.
221. Guglielmi A, Barni S, Zaniboni A, Pella N, Belvedere O, Beretta GD, **Grossi F**, Frontini L, Puglisi F, Labianca R, Sobrero A; Gruppo Italiano Studio Carcinomi Apparato Digerente. Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. Br J Cancer. 2004 Oct 18;91(8):1428-33.
222. **Grossi F**, Belvedere O, Fasola G, Barbone F, Rizzato S, Sibau A, Recchia L, Vigevani E, Ceschia T, Morelli A, Guglielmi A, Puglisi F, Follador A, Talmassons G, Sobrero AF. Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer. 2004 Oct;46(1):99-106.
223. Belvedere O, Minisini A, Ramello M, Sobrero A, **Grossi F**. Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective. Eur J Cancer. 2004 Aug;40(12):1850-4.
224. **Grossi F**, Loprevite M, Chiaramondia M, Ceppa P, Pera C, Ratto GB, Serrano J, Ferrara GB, Costa R, Boni L, Ardizzoni A. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer. 2003 Jun;39(9):1242-50.
225. Baas P, Ardizzoni A, **Grossi F**, Nackaerts K, Numico G, Van Marck E, van de Vijver M, Monetti F, Smid-Geirnaerd MJ, van Zandwijk N, Debruyne C, Legrand C, Giaccone G; EORTC Lung Cancer Group. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer. 2003 Feb;39(3):353-7.
226. **Grossi F**, Belvedere O, Rosso R. Geography of clinical cancer research publications from 1995 to 1999. Eur J Cancer. 2003 Jan;39(1):106-11.
227. **Grossi F**, Pennucci MC, Serrano J, Frola C, Mereu C, Scolaro T, Ratto GB, Tixi L, Ardizzoni A. Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer. Anticancer Res. 2002 Nov-Dec;22(6B):3519-24.
228. Loprevite M, Favoni RE, de Cupis A, Pirani P, Pietra G, Bruno S, **Grossi F**, Scolaro T, Ardizzoni A. Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines. Lung Cancer. 2001 Jul;33(1):27-39.
229. Sobrero A, Puglisi F, Guglielmi A, Belvedere O, Aprile G, Ramello M, **Grossi F**. Fatigue: a main component of anemia symptomatology. Semin Oncol. 2001 Apr;28(2 Suppl 8):15-8.
230. Sobrero A, Guglielmi A, Cirillo M, Recaldin E, Frassinetti GL, Aschele C, Ravaioli A, Testore P, Caroti C, Gallo L, Pessi MA, Cortesi E, Turci D, **Grossi F**, Labianca R. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. Br J Cancer. 2001 Apr 20;84(8):1023-8.
231. **Grossi F**, Scolaro T, Tixi L, Loprevite M, Ardizzoni A. The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. Crit Rev Oncol Hematol. 2001 Jan;37(1):61-7.
232. Ardizzoni A, **Grossi F**, Salvati F, Silvano G, Santi L. Managing patients with lung cancer. Common international guidelines must be developed.

- BMJ. 2000 Feb 5;320(7231):380.
233. Sobrero A, Zaniboni A, Frassinetti GL, Aschele C, Guglielmi A, Giuliani R, Ravaioli A, Lanfranco C, Caroti C, Arnoldi E, Barni S, Gallo L, Pessi MA, Turci D, Cortesi E, **Grossi F**, Frontini L, Piazza E, Bruzzi P, Labianca R.  
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.  
Ann Oncol. 2000 Nov;11(11):1413-20.
234. Ardizzoni A, **Grossi F**.  
Update on the treatment of small cell lung cancer (SCLC).  
Ann Oncol. 2000;11 Suppl 3:101-8.
235. Sobrero A, Guglielmi A, **Grossi F**, Puglisi F, Aschele C.  
Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.  
Semin Oncol. 2000 Oct;27(5 Suppl 10):72-7.
236. Sobrero A, **Grossi F**, Guglielmi A.  
Role of oxaliplatin in the treatment of colorectal neoplasms.  
Tumori. 2000 May-Jun;86(3 Suppl): S3-5.
237. Ardizzoni A, Antonelli G, **Grossi F**, Tixi L, Cafferata M, Rosso R.  
The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC).  
Ann Oncol. 1999;10 Suppl 5: S13-7.
238. Ardizzoni A, **Grossi F**, Scolaro T, Giudici S, Foppiano F, Boni L, Tixi L, Cosso M, Mereu C, Ratto GB, Vitale V, Rosso R.  
Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer  
Br J Cancer. 1999 Sep;81(2):310-5.
239. Loprevite M, Favoni RE, de Cupis A, Pirani P, Merlo F, **Grossi F**, Ardizzoni A.  
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.  
Int J Oncol. 1999 Oct;15(4):787-92.
240. Ardizzoni A, **Grossi F**, Meazza R, Ferrini S.  
New perspectives for the pharmacological and biological therapy of small cell lung cancer.  
Crit Rev Oncol Hematol. 1999 Jul;31(2):135-45.
241. Ardizzoni A, **Grossi F**, Pennucci MC.  
Systemic drug therapy of malignant pleural mesothelioma.  
Monaldi Arch Chest Dis. 1998 Apr;53(2):236-40.
242. **Grossi F**, Pennucci MC, Tixi L, Cafferata MA, Ardizzoni A.  
Management of malignant pleural effusions.  
Drugs. 1998 Jan;55(1):47-58.
243. Loprevite M, Varesco L, Favoni R, Ferrara GB, Moro F, Ottaggio L, Fronza G, Campomenosi P, Abbondandolo A, Cutrona G, Roncella S, Albini A, Aluigi MG, Pozzi S, Pera C, Biticchi R, Gismondi V, **Grossi F**, Pennucci MC, Ardizzoni A.  
Analysis of K-ras, p-53, bcl-2 and Rb expression in non-small cell lung cancer (NSCLC) cell lines.  
Int J Oncol. 1997 11: 1203-1208.
244. **Grossi F**, Sobrero A.  
The clinical management of early and advanced colorectal cancer.  
Adv Clin Path. 1997 Oct;1(4):261-267.
245. Guglielmi A, Aschele C, **Grossi F**, Tixi L, Sobrero A.

Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.  
Cytotechnology. 1996;19(3):215-9.

246. Melloni E, Pontremoli S, Sparatore B, Patrone M, **Grossi F**, Marks PA, Rifkind RA.  
Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells.  
Proc Natl Acad Sci USA. 1990 Jun;87(12):4417-20.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Varese, 19 luglio 2022

Prof. Francesco Grossi